1.Biological characteristics of coxsackievirus A6 clinical isolates
Xin HE ; Ting YANG ; Hua LI ; Lei YUE ; Xia SONG ; Tianhong XIE ; Weijie GAO ; Zhongping XIE
Chinese Journal of Microbiology and Immunology 2019;39(4):241-249
Objective To analyze the biological characteristics of clinical isolates of coxsackievir-us A6 (CVA6), a pathogen of hand,foot and mouth disease (HFMD), and to provide reference for vaccine development. Methods CVA6 strains were isolated from 21 stool and throat swab specimens of patients with HFMD in Yunnan Province and then identified. Their growth characteristics, plaque morphology and virulence to suckling mice were analyzed. Results Five CVA6 strains, named CVA6-129, CVA6-113, CVA6-57, CVA6-94 and CVA6-162, were isolated and all belonged to D3 subtype. Only the CVA6-129 strain could proliferate rapidly in Vero and KMB17 cells and the proliferation peaked 30 h after inoculation. The infectious titer of the CVA6-129 strain was 7. 54 lgCCID50 (50% cell culture infective dose) / ml in KMB17 cells. Different morphologies of plaques were formed by the CVA6-129 strain in Vero and KMB17 cells at the same time points, which were small and round with clear edges in Vero cells, and large and irregular with blurry edges in KMB17 cells. Suckling mice were susceptible to CVA6 via intramuscular and intraperito-neal injection. The most common symptoms in infected suckling mice were reduced mobility, hind limb pa-ralysis and quadriplegia. CVA6 infection could result in death in severe cases. Conclusions This study isolated five CVA6 strains from a number of clinical samples of suspected HFMD cases, of which the CVA6-129 strain showed potential as a vaccine candidate.
2.Expression and clinical significance of CREB3L1 in gastric cancer
Shaobin YUAN ; Tianhong XIA ; Xiaomeng CAO ; Chang′an GUO ; Zhichang LIU ; Hongbin LIU
International Journal of Surgery 2023;50(1):31-36,C3
Objective:To investigate the expression and clinical significance of cAMP response element-binding protein 3-like 1 (CREB3L1) in gastric cancer.Methods:A total of 97 patients who received surgical resection of gastric cancer in Lanzhou University Second Hospital from Jan. 2019 to Dec. 2020 were selected as the study subjects. Immunohistochemistry was used to detect the expression level of CREB3L1 in gastric cancer tissues and matched paracancer tissues. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect the expression level of CREB3L1 in gastric cancer and adjacent tissues. Statistical methods were used to analyze the relationship between the expression level of CREB3L1 in gastric cancer tissues and the degree of differentiation of tumor cells, tumor size, depth of invasion, TNM staging and other clinicopathological data, and Logistic regression analysis was used to study the risk factors of gastric cancer. To explore the clinical significance of CREB3L1 expression level in gastric cancer.Results:Immunohistochemical results showed that CREB3L1 protein was mainly expressed in the nucleus. The positive rate in gastric cancer tissues was 17.5% (17 cases), which was lower than that in normal adjacent tissues 84.5% (82 cases), and the difference was statistically significant ( χ2=87.15, P<0.001). qRT-PCR was used to detect the expression of CREB3L1 in gastric cancer and adjacent tissues. The results showed that the expression level of CREB3L1 was significantly higher in adjacent tissues than in cancer cells. The results were statistically significant ( P<0.05). The positive expression rate of CREB3L1 was decreased in the cancer tissues of gastric cancer patients, and its expression level was correlated with the degree of tumor differentiation, tumor size, invasion depth and TNM stage ( P<0.05), but not with Lauren classification and tumor location ( P>0.05). Logistic regression analysis showed that the positive expression level of CREB3L1 was correlated with the degree of tumor differentiation in gastric cancer patients ( P<0.05). Conclusion:The expression of CREB3L1 is decreased in gastric cancer, which is related to the degree of tumor differentiation, tumor size, invasion depth and TNM stage, which is of great value in early and accurate diagnosis of benign and malignant gastric cancer.
3.The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China
Yang YANG ; Zhongjun XIA ; Wenhao ZHANG ; Chengcheng FU ; Li BAO ; Bing CHEN ; Kaiyang DING ; Sili WANG ; Jun LUO ; Bingzong LI ; Luoming HUA ; Wei YANG ; Xin ZHOU ; Liang WANG ; Tianhong XU ; Weida WANG ; Guolin WU ; Yun HUANG ; Jing LI ; Peng LIU
Chinese Journal of Hematology 2021;42(8):628-634
Objective:To evaluate the efficacy and safety profile of ixazomib/lenalidomide/dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM) .Methods:This study comprising 14 medical centers in China included patients with relapsed/refractory MM who received at least. Ixazomib at an initial oral dose of 4 mg was administered. Seven patients had dose adjustment to 3 mg at the time of first dose. The lenalidomide doses were adjusted according to creatinine clearance rate. The efficacy and safety were evaluated every cycle.Results:In the study cohort of 74 patients, the median age was 65 years and 11 (14.9% ) patients received over three lines of therapy. Overall response rate (ORR) was 54.1% (40/74) , and 7 (9.5% ) , 14 (18.9% ) , and 19 (25.7% ) patients achieved stringent complete response or complete response, very good partial response, and partial response, respectively. The median progression-free survival and overall survival were 9.9 and 20 months, respectively. The median time to response was 1 month. The efficacy and survival outcome were similar to those reported in the Tourmaline-MM1 China Continuous Study. The ORR of patients refractory to bortezomib, lenalidomide, and bortezomib plus lenalidomide were 52.0% (13/25) , 57.1% (4/7) , and 33.3% (6/18) , respectively. The rate of grade 3-4 adverse events was 36.5% (27/74) . Common hematological toxicities were anemia, thrombocytopenia, lymphopenia, and neutropenia. Common non-hematological toxicities were fatigue, gastrointestinal symptoms, and infections. Two cases of grade 3 peripheral neuropathy were reported. The patients eligible for the Tourmaline-MM1 China Continuous Study had a higher ORR than the ineligible patients [77.8% (14/18) vs 46.4% (26/56) , P=0.020]. There was no difference in the rate of grade 3-4 adverse events [33.3% (6/18) vs 37.5% (21/56) , P=0.749]. Conclusion:The IRd regimen had good efficacy and acceptable toxicity in Chinese patients with relapsed/refractory MM.
4.Syndrome Differentiation and Treatment of Allergic Rhinitis in Children Based on the Theory of "Five Viscera Correlation"
Tianhong XU ; Ziyu ZHU ; Xia ZHAO ; Min LI
Journal of Nanjing University of Traditional Chinese Medicine 2024;40(11):1155-1160
The theory of"five viscera correlation"summarizes the long-term clinical practice of traditional Chinese medicine,ex-plains the physiological and pathological phenomena of the human body from a multi-dimensional perspective of system correlation,and guides the diagnosis and prevention of diseases.Syndrome differentiation and treatment of allergic rhinitis in children should be based on the theory of"five viscera correlation"combined with the physiological characteristics of deficiency and excess of the five viscera of children;make it clear that the location of the disease is inseparable from the nasal orifice and the pathogenesis is inseparable from the five viscera;in terms of syndrome differentiation and treatment,the viscera should be regulated and the orifice should be regulated via the viscera;on the basis of identifying the cause and examining the pathogenesis,attention should be paid to regulating the lungs and spleen,tonifying the kidneys,clearing the heart,and soothing the liver,so as to restore the harmony of the viscera and the unobstruct-ed nasal orifice.
5.Interference of CD38 monoclonal antibody in blood compatibility testing and its countermeasures: A general consensus among experts
Jianqing MI ; Xiaohong CAI ; Shaoyuan WANG ; Lihua HU ; Ting NIU ; Deqing WANG ; Chengcheng FU ; Chunyan SUN ; Dong XIANG ; Wen GAO ; Tianhong MIAO ; Liye ZHONG ; Baohua QIAN ; Gang AN ; Rong XIA ; Rong GUI ; Jing LIU ; Xiaofeng TANG ; Jue XIE ; Jia GAN ; Jiang WU ; Danhui FU ; Li QIN ; Jian HOU ; Xuefeng WANG
Chinese Journal of Blood Transfusion 2021;34(4):327-334
With continuous discovery of tumor immune targets and continuous changes in antibody research and development technology, antibody drugs are becoming more and more widely used in clinical practice. However, some targets are not only expressed on tumor cells, but also on red blood cells. Therefore, the clinical application of antibodies against the corresponding targets may interfere with the detection of blood transfusion compatibility, resulting in difficulty in blood matching or delay of blood transfusion. This consensus summarizes the current solutions for the interference of CD38 monoclonal antibody (CD38 mAb) in transfusion compatibility testing. After analyzing the advantages and disadvantages of different methods, polybrene and sulfhydryl reducing agents [dithiothreitol (DTT) or 2-mercaptoethanol (2-Me)], as a solution for CD38 mAb interference in blood compatibility testing, are recommended for Chinese patients, so as to eliminate blood transfusion interference produce by CD38 mAb and further provide a pre-transfusion workflow for clinicians and technicians in Department of Blood Transfusion.